Abstract
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
Cite
CITATION STYLE
APA
Haley, C. A., Macias, P., Jasuja, S., Jones, B. A., Rowlinson, M. C., Jaimon, R., … Goswami, N. D. (2021). Novel 6-month treatment for drug-resistant tuberculosis, United States. Emerging Infectious Diseases, 27(1), 332–334. https://doi.org/10.3201/eid2701.203766
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free